MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202517060877 A) filed by Neumora Therapeutics, Inc., Watertown, U.S.A., on June 25, for 'modulators of nlrp3 inflammasome and related products and methods.'
Inventor(s) include Beausoleil, Anne-Marie; and Hudson, Ryan.
The application for the patent was published on Aug. 8, under issue no. 32/2025.
According to the abstract released by the Intellectual Property India: "Compounds are provided for inhibiting NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (A'): (A') or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein ring A, Z1, Z2, R1, R2, R3, R4, n, and p are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided."
The patent application was internationally filed on Dec. 21, 2023, under International application No.PCT/US2023/085527.
Disclaimer: Curated by HT Syndication.
